Figure 2From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus Median remogliflozin etabonate (prodrug) concentration vs. time profiles with and without metformin, n = 13. (Median data is presented in this plot because the majority of the samples were below the lower limit of quantification).Back to article page